FEDERAL COURT OF AUSTRALIA
Apotex Pty Ltd v Les Laboratoires Servier (No 2) [2012] FCA 748
Citation: Apotex Pty Ltd v Les Laboratoires Servier (No 2)
[2012] FCA 748Parties: APOTEX PTY LTD ACN 096 916 148 v LES LABORATOIRES SERVIER; LES LABORATOIRES SERVIER and SERVIER LABORATORIES (AUST) PTY LTD ACN 004 838 500; APOTEX PTY LTD and SYMBION PTY LTD ACN 000 875 034 File number: NSD 51 of 2012 Judge: BENNETT J Date of judgment: 13 July 2012 Catchwords: PRACTICE & PROCEDURE – Service outside Australia – whether overseas entities that were part of the same corporate group should be joined to proceeding – whether Court has a discretion to make or refuse an order granting leave to serve a party outside Australia under Rule 10.43 Federal Court Rules 2011
PATENTS – prima facie case – authorisation of infringement – joint tortfeasorship by common design
PRACTICE & PROCEDURE – Quia timet relief – whether available in circumstances where there is an interim injunction by consent – no primary infringement and no threat of a primary infringement
Legislation: Copyright Act 1968 (Cth) s 101(1A)
Federal Court Rules 2011, Division 1.2, 1.3 and 10.4, Rules 10.42 and 10.43
Federal Court of Australia Act 1976 (Cth) s 37M
Patents Act 1990 (Cth) s 13 and Schedule 1
Therapeutic Goods Act 1989 (Cth) s 3(1)Cases cited: Alcoa of Australia Ltd (ACN 004 879 298) v Australian Workers’ Union (2010) 196 IR 103 followed
Apotex Pty Ltd v Les Laboratoires Servier (No 4) (2010) 89 IPR 274 distinguished
Australasian Performing Right Association Ltd v Metro on George (2004) 210 ALR 244 cited
Bell v Steele (2011) 198 FCR 291
Bray v F Hoffman-La Roche (2002) 118 FCR 1 cited
CSL Ltd v Glaxosmithkline (2006) 70 IPR 128 cited
Century Insurance(in provisional liquidation) v New Zealand Guardian Trust [1996] FCA 376 cited
Ho v Akai Pty Ltd (in liq) (2006) 24 ACLC 1526 followed
Humane Society International Inc v Kyodo Senpaku Kaisha Ltd (2006) 154 FCR 425 cited
Inverness Medical Switzerland GMBH v MPS Diagnostics Pty Ltd (2010) 85 IPR 525 cited
Magic Menu Systems Pty Ltd v AFA Facilitation Pty Ltd (1997) 72 FCR 261 cited
MeadCorporation v Riverwood Multiple Packaging [1997] FSR 484 cited
Morton-Norwich Products Inc v Intercen Limited [1978] RPC 501 followed
Nationwide News Pty Ltd v Copyright Agency Ltd (1996) 65 FCR 399 cited
Perdaman Chemicals and Fertilisers v Griffin Coal Mining Co Pty Ltd [2011] FCA 1425 cited
RCA Corporation v John Fairfax Sons [1981] 1 NSWLR 251 cited
Roadshow Films Pty Ltd v iiNetPty Ltd (2012) 286 ALR 466 discussed
Sigma Pharmaceuticals (Australia) Pty Ltd v Wyeth (2010) 88 IPR 459 cited
Sigma Pharmaceuticals (Australia) Pty Ltd v Wyeth (2010) 88 IPR 633 cited
Suzlon Energy Ltd v Bangad (No 3) [2012] FCA 123 cited
Unilever PLC v ChefaroProprietaries Ltd [1994] FSR 15 discussed
Unilever PLC v Gillette (UK) Ltd [1989] distinguished
WEA International v Hanimex Corp Ltd (1987) 17 FCR 274
Keep reading for free
Create a free CaseChat account to read Apotex Pty Ltd v Les Laboratoires Servier (No 2) and more:
- Read every judgment in full
- Ask AI and get answers linked to paragraphs
- See how each paragraph was cited in later cases
- Download judgments as PDF or Word
One click creates your free account or signs you in.
By continuing you agree to the Terms and Privacy Policy.
- Case
- [2012] FCA 748
- Decision Date
CaseChat Overview and Summary
The court examined whether there was sufficient evidence to support a prima facie case of infringement by the overseas entities. Servier argued that each of the overseas entities manufactured and supplied pharmaceutical products for sale in Australia, and that Apotex Inc also imported such products. The court considered the corporate structure of the Apotex group and whether the overseas entities were sufficiently connected to Apotex Pty Ltd to be considered part of a common design or authorisation to infringe the patent. The court found that there was insufficient evidence to support the inference that the overseas entities were involved in a common design or authorisation to infringe the patent.
The court concluded that there was no present infringement of the patent and no present threat of an infringement. The court held that there was no basis for a quia timet injunction because there was no actual or apprehended infringement and no other party to the joint tortfeasance by common design or an infringement, actual or apprehended to be authorised. The court further held that an injunction must be of some practical utility and the court should not enjoin conduct that in all probability will not occur.
The court's decision was based on the specific circumstances of the case, including the fact that Apotex Pty Ltd had proffered consent to an injunction and had admitted that the product in question was within the scope of the patent claims. The court held that if the patent was determined to be invalid, there could be no infringement, and if the patent was valid, Apotex Pty Ltd would be subject to a permanent injunction restraining exploitation of the product. The court also noted that there was no evidence that Apotex Pty Ltd would sell or attempt to sell the product if the patent were held to be valid or pending the determination of the validity of the patent.
The court's decision highlights the importance of establishing a prima facie case of infringement and the need for sufficient evidence to support a claim of joint tortfeasance by common design or authorisation. The decision also emphasises the need for an injunction to be of some practical utility and not to enjoin conduct that in all probability will not occur. The case serves as a reminder that the grant of an injunction is not automatic and requires careful consideration of the specific circumstances of each case.
Orders
Orders of the court
Full text does not contain this section.
Background
Background to the litigation
Full text does not contain this section.
Evidence
Evidence Before The Court
Decision
Reasons for decision
Ratio Decidendi
Legal Principle Established
Apotex P/L emphasises that:·because of the injunction restraining the sale, or other exploitation by it, of the Apotex Product, there is no tort being committed;·there is no question of damage presently arising or likely to arise;·infringement is not in issue;·if the Patent is valid, there will be no relevant exploitation by Apotex P/L in Australia; and·if the Patent is invalid, there will be no damage suffered by Servier if Apotex P/L then sells the Apotex Product. Consideration In Apotex (No 4), I considered whether parties could be joined to the proceeding if they were considered joint tortfeasors by common design and authorisation. In that case, the accumulation of evidence was held sufficient to support a case of common design and an order for joinder of the overseas company Apotex Pharmachem. This evidence included:·the existence of a vertically integrated group of companies, including Apotex P/L and Apotex Pharmachem;·manufacture of the active pharmaceutical ingredient (API) of the Australian product by Apotex Pharmachem;·the sale of the allegedly infringing product in Australia by Apotex P/L;·Apotex Pharmachem provided information and played an active role in obtaining approval for the Australian product under the Therapeutic Goods Act 1989 (Cth) (TG Act); and·Apotex Pharmachem manufactured the API in circumstances where it knew of the patent that was in dispute in that proceeding. There are differences between the present circumstances and those that existed in Apotex (No 4), including:·the allegedly infringing products were being sold in Australia and this conduct was not the subject of an interim injunction;·Apotex Pharmachem’s manufacture of the API and its role in obtaining and maintaining Therapeutic Goods Administration (TGA) approval was in that context; and·infringement was in issue and joinder was pressed in part to obtain information from Apotex Pharmachem, as the manufacturer of the API, said to be necessary for Servier’s case on infringement. Servier relies on the decision in Unilever PLC v Gillette (UK) Ltd [1989] RPC 583. In that case, the plaintiffs referred to a number of factors said to found an inference that an overseas parent company was involved in a common design with the local UK company. The factors were that the overseas parent company:1.wholly owned Gillette UK (through another subsidiary);2.sold the allegedly infringing product to Gillette UK;3.was aware of the patent at the time of sale;4.was party to a know-how agreement with Gillette UK;5.exercised a worldwide right to veto products intended to be marketed by the Gillette group; and6.benefited financially from sales both through direct profits and royalties payable under the know-how and licence agreement. The majority of the Court in that case found that although there were strong arguments both ways, the factors established a “good arguable case” for common design, sufficient to grant leave to join the overseas parent company to the proceedings. However, as in the comparison with Apotex (No 4) above, there are differences between the present circumstances and those that existed in Unilever v Gillette.